Private Advisor Group LLC Decreases Holdings in Haleon plc (NYSE:HLN)

Private Advisor Group LLC reduced its position in Haleon plc (NYSE:HLN) by 2.8% in the 3rd quarter, Holdings Channel reports. The firm owned 48,234 shares of the company’s stock after selling 1,393 shares during the period. Private Advisor Group LLC’s holdings in Haleon were worth $510,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Cultivar Capital Inc. acquired a new stake in shares of Haleon in the 2nd quarter valued at about $40,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Haleon during the 1st quarter worth approximately $43,000. Hexagon Capital Partners LLC raised its stake in shares of Haleon by 66.6% during the 2nd quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock worth $55,000 after buying an additional 2,677 shares in the last quarter. BOKF NA raised its stake in shares of Haleon by 68.8% during the 2nd quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after buying an additional 2,842 shares in the last quarter. Finally, Rothschild Investment LLC purchased a new position in shares of Haleon during the 2nd quarter worth approximately $60,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Trading Up 0.3 %

NYSE:HLN opened at $9.76 on Tuesday. The business’s 50-day moving average is $10.23 and its two-hundred day moving average is $9.27. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The firm has a market capitalization of $44.18 billion, a PE ratio of 28.85, a price-to-earnings-growth ratio of 2.83 and a beta of 0.30.

Analyst Ratings Changes

Several research firms recently weighed in on HLN. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. UBS Group upgraded Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Morgan Stanley raised their price objective on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. Finally, Berenberg Bank started coverage on Haleon in a report on Tuesday, August 6th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.